Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Phases › Phase 1

Phase 1 (131 companies)

Companies with at least one active program at Phase 1.

Ticker Company Therapeutic areas Phase 1 programs Lead stage Programs
ABSI Absci DermatologyGI/Hepatology+1 3 Phase 1 6
ACIU AC Immune Neurology Rare 5 Phase 3 10
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 2 Phase 2 8
ACRV Acrivon Therapeutics Oncology 1 Phase 2 6
ACTU Actuate Therapeutics Oncology 2 Phase 2 4
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 4
ADAG Adagene Oncology 4 Phase 2 10
ACET Adicet Bio ImmunologyNeurology+2 Rare 7 Phase 1 8
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved 10
AKTS Aktis Oncology Oncology 10 Phase 1 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 Rare 1 NDA Submitted 7
ALLO Allogene Therapeutics ImmunologyOncology Rare 5 Phase 2 10
DRTS Alpha Tau Medical Oncology 1 Phase 2 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 5
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 3 Approved 6
ANIX Anixa Biosciences Oncology 2 Phase 1 3
ANNX Annexon HematologyNeurology+2 Rare 2 Phase 3 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 5 Phase 2 9
APVO Aptevo Therapeutics Oncology 2 Phase 1 8
RCUS Arcus Biosciences DermatologyImmunology+1 1 Phase 3 6
ARTV Artiva Biotherapeutics DermatologyImmunology+2 Rare 5 Phase 2 14
ARVN Arvinas NeurologyOncology Rare 8 Approved 12
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 9 Approved 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 4 Phase 2 6
BCAX Bicara Therapeutics Oncology 3 Phase 2 4
BIOA BioAge Labs CardiovascularOphthalmology 1 Phase 2 2
BMEA Biomea Fusion MetabolicOncology 2 Phase 2 4
BCTX BriaCell Therapeutics Oncology 1 Phase 3 7
BBOT BridgeBio Oncology Therapeutics Oncology 8 Phase 1 8
CCCC C4 Therapeutics Oncology 1 Phase 2 2
CABA Cabaletta Bio DermatologyImmunology+2 Rare 7 Phase 1 8
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted 2
CRBU Caribou Biosciences Oncology 3 Phase 1 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 2 Phase 3 4
CLDX Celldex Therapeutics DermatologyImmunology+1 1 Phase 3 7
CLRB Cellectar Biosciences Oncology 2 Phase 2 6
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 4 Phase 1 9
CLYM Climb Bio HematologyImmunology+1 Rare 5 Phase 2 7
COGT Cogent Biosciences HematologyOncology Rare 3 NDA Submitted 7
CHRS Coherus Oncology Oncology 1 Approved 3
CMPX Compass Therapeutics Oncology 7 Phase 2 9
CGEN Compugen Oncology 2 Phase 3 7
CBIO Crescent Biopharma Oncology 8 Phase 2 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 2 Approved 6
CUE Cue Biopharma ImmunologyOncology 2 Phase 2 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 6 NDA Submitted 10
CTMX CytomX Therapeutics Oncology 5 Phase 1 6
DBVT DBV Technologies Immunology 1 NDA Submitted 2
EIKN Eikon Therapeutics Oncology 10 Phase 2 13
ELTX Elicio Therapeutics Oncology 2 Phase 2 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 2 Phase 2 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 2 Phase 2 6
ENTX Entera Bio GI/HepatologyMetabolic Rare 1 Phase 2 4
ERAS Erasca Oncology 2 Phase 1 3
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+2 Rare 1 Approved 14
EXEL Exelixis CardiovascularOncology 6 Approved 22
FHTX Foghorn Therapeutics Oncology 1 Phase 1 5
FBRX Forte Biosciences DermatologyGI/Hepatology 2 Phase 2 3
GANX Gain Therapeutics MetabolicNeurology Rare 1 Phase 1 5
GNLX Genelux Oncology 1 Phase 3 3
GHRS GH Research NeurologyWomen's Health 1 Phase 2 4
IMTX Immatics Oncology 7 Phase 2 8
IMMX Immix Biopharma Hematology Rare 1 Phase 1 1
IMRX Immuneering Oncology 4 Phase 3 5
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 4
IBRX ImmunityBio Infectious DiseaseOncology 5 Approved 16
IMNM Immunome Oncology Rare 6 NDA Submitted 9
INAB IN8bio ImmunologyOncology 2 Phase 2 6
INSM Insmed CardiovascularDermatology+2 Rare 2 Approved 9
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 4
JANX Janux Therapeutics Oncology 2 Phase 1 3
KAPA Kairos Pharma Oncology 1 Phase 2 9
KPRX Kiora Pharmaceuticals Ophthalmology Rare 1 Phase 2 4
KURA Kura Oncology MetabolicOncology 8 Approved 12
KYMR Kymera Therapeutics DermatologyRespiratory Rare 2 Phase 2 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 2 NDA Submitted 7
LEGN Legend Biotech Oncology Rare 7 Approved 8
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 3 Phase 1 8
LCTX Lineage Cell Therapeutics NeurologyOphthalmology Rare 1 Phase 2 5
MRKR Marker Therapeutics Oncology 3 Phase 1 4
MDNAF Medicenna Therapeutics Oncology 2 Phase 2 9
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 7
GLUE Monte Rosa Therapeutics CardiovascularDermatology+2 Rare 4 Phase 2 6
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 11
NGEN NervGen Pharma Neurology 1 Phase 1 3
NKTX Nkarta ImmunologyNeurology+1 Rare 8 Phase 1 8
NBP NovaBridge Biosciences OncologyOphthalmology 3 Phase 2 6
NRIX Nurix Therapeutics ImmunologyNeurology+1 11 Phase 3 16
NVCT Nuvectis Pharma HematologyOncology+1 Rare 5 Phase 3 8
OCGN Ocugen Infectious DiseaseOphthalmology Rare 4 Phase 3 12
OMER Omeros HematologyNeurology+2 Rare 2 Approved 6
IRD Opus Genetics Ophthalmology Rare 2 Approved 14
OVID Ovid Therapeutics Neurology Rare 1 Phase 2 4
PALI Palisade Bio Immunology 2 Phase 1 3
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 4
CATX Perspective Therapeutics Oncology 4 Phase 1 4
PHIO Phio Pharmaceuticals Oncology 3 Phase 1 4
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 4 Phase 1 5
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 7
PMN ProMIS Neurosciences Neurology Rare 1 Phase 1 6
RLAY Relay Therapeutics DermatologyOncology Rare 1 NDA Submitted 4
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved 13
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 2 Approved 4
SGMT Sagimet Biosciences DermatologyMetabolic 1 NDA Submitted 3
SANA Sana Biotechnology MetabolicOncology 1 Phase 1 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 4 Approved 10
SCYX Scynexis Infectious DiseaseRenal Rare 3 Approved 5
SION Sionna Therapeutics Respiratory Rare 4 Phase 2 5
SLDB Solid Biosciences CardiovascularNeurology Rare 2 Phase 3 6
GPCR Structure Therapeutics MetabolicRespiratory Rare 2 Phase 3 5
STRO Sutro Biopharma Oncology 1 Phase 1 4
TNGX Tango Therapeutics Oncology 4 Phase 1 4
TECX Tectonic Therapeutic Cardiovascular Rare 1 Phase 2 3
TGTX Tg Therapeutics Neurology Rare 2 Approved 6
TYRA Tyra Biosciences MetabolicOncology Rare 2 Phase 2 5
UNCY Unicycive Therapeutics Renal 1 NDA Submitted 2
QURE uniQure HematologyMetabolic+1 Rare 3 Approved 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 5 Approved 29
PCVX Vaxcyte Infectious Disease 1 Phase 3 6
VKTX Viking Therapeutics MetabolicNeurology Rare 2 Phase 3 8
VIR Vir Biotechnology Infectious DiseaseOncology Rare 8 Phase 3 10
VRDN Viridian Therapeutics ImmunologyOphthalmology 2 Approved 5
VYGR Voyager Therapeutics MetabolicNeurology Rare 1 Phase 1 9
VTVT vTv Therapeutics MetabolicRespiratory Rare 1 Phase 3 8
WVE Wave Life Sciences MetabolicNeurology+1 Rare 3 Phase 2 5
XNCR Xencor HematologyImmunology+4 Rare 21 Approved 36
XENE Xenon Pharmaceuticals Neurology Rare 4 Phase 3 8
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 3 NDA Submitted 11
ZURA Zura Bio DermatologyImmunology Rare 1 Phase 2 5
ZYME Zymeworks OncologyRespiratory 4 Approved 11